- Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma
-
Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W, Bakhtiar UI Islam SM
- KMID: 2373123
- Clin Mol Hepatol.
- 2016 Jun;22(2):267-271.
- doi: 10.3350/cmh.2015.0017
The bone is a common site for metastasis in hepatocellular carcinoma (HCC). However, bone marrow metastasis from HCC is rarely reported, and its frequency is unclear. Here we report a... -
- CITED
-
- Close
- SHARE
-
- Close
- The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
-
Kang K, Kim JH, Kang SH, Lee BJ, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS
- KMID: 2380768
- Gut Liver.
- 2015 Mar;9(2):224-230.
- doi: 10.5009/gnl14047
BACKGROUND/AIMS: Prothrombin induced by vitamin K deficiency or antagonist II (PIVKA-II) is a widely used diagnostic marker for hepatocellular carcinoma (HCC). We evaluated the correlation between alcoholic liver disease (ALD)... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation
-
Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW, Suh KS
- KMID: 1788569
- Clin Mol Hepatol.
- 2014 Jun;20(2):192-203.
- doi: 10.3350/cmh.2014.20.2.192
BACKGROUND/AIMS: The most commonly used immunosuppressant therapy after liver transplantation (LT) is a combination of tacrolimus and steroid. Basiliximab induction has recently been introduced; however, the most appropriate immunosuppression for... -
- CITED
-
- Close
- SHARE
-
- Close
